Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 18/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4935472 | 0.95 | FDFT1 (0.69) | FDFT1 | |
| SCHEMBL4933576 | 0.90 | FDFT1 (0.61) | FDFT1 | |
| SCHEMBL4938335 | 0.89 | FDFT1 (0.70) | FDFT1 | |
| SCHEMBL4934415 | 0.89 | FDFT1 (0.70) | FDFT1 | |
| SCHEMBL14070211 | 0.87 | FDFT1 (0.63) | FDFT1 | |
| SCHEMBL4927661 | 0.85 | FDFT1 (0.69) | FDFT1 | |
| SCHEMBL4934232 | 0.85 | FDFT1 (0.62) | FDFT1 | |
| SCHEMBL14070143 | 0.85 | FDFT1 (0.70) | FDFT1 | |
| SCHEMBL4932402 | 0.84 | FDFT1 (0.69) | FDFT1 | |
| SCHEMBL4933104 | 0.83 | FDFT1 (0.68) | FDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082333-A1 | REMEDY FOR XANTHOMA | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2009-03-26 | — | — | US | claimed |
| US-20080227770-A1 | Benzoxazepine Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-18 | — | — | US | claimed |
| EP-1889632-A1 | REMEDY FOR XANTHOMA | National University Corp. Kobe University (JP) | 2008-02-20 | — | — | EP | claimed |
| EP-1650201-A1 | BENZOXAZEPINE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2006-04-26 | — | — | EP | claimed |
| US-20090209510-A1 | Novel Method of Treating Hyperlipidemia | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-20 | — | — | US | disclosed |
| US-20090082333-A1 | REMEDY FOR XANTHOMA | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20080227770-A1 | Benzoxazepine Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-18 | — | — | US | disclosed |
| US-20080227770-A1 | Benzoxazepine Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-18 | — | — | US | disclosed |
| US-20080227770-A1 | Benzoxazepine Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-18 | — | — | US | disclosed |
| EP-1889632-A1 | REMEDY FOR XANTHOMA | National University Corp. Kobe University (JP) | 2008-02-20 | — | — | EP | disclosed |
| EP-1650201-A1 | BENZOXAZEPINE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2006-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082333-A1 | REMEDY FOR XANTHOMA | FDFT1, LSS, SQLE | FDFT1 1/4885 |
| US-20090209510-A1 | Novel Method of Treating Hyperlipidemia | HMGCR, LIPC, LIPA | FDFT1 12/4885 |
| US-20080227770-A1 | Benzoxazepine Compound | NR1H2, SQLE, NR1H3 | FDFT1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.